[Immunotherapy in lung cancer: checkpoint inhibitors]

Thomas Wehler; Beatrice Wehler; Ingo Stehle

doi:10.1055/s-0041-107770

[Immunotherapy in lung cancer: checkpoint inhibitors]

Dtsch Med Wochenschr. 2015 Dec;140(24):1835-8. doi: 10.1055/s-0041-107770. Epub 2015 Dec 1.

[Article in German]

Authors

Thomas Wehler¹, Beatrice Wehler², Ingo Stehle³

Affiliations

¹ Thoraxonkologie, Klinik für Innere Medizin V, Pneumologie, Allergologie, Beatmungs- und Umweltmedizin, Universitätsklinikum des Saarlandes.
² III. Medizinsche Klinik und Poliklinik, Schwerpunkt Hämatologie, Internistische Onkologie und Pneumologie, Universitätsmedizin Mainz und Universitäres Centrum für Tumorerkrankungen (UCT) Mainz.
³ Onkologische Gemeinschaftspraxis, Schneiderstr. 12, 67655 Kaiserslautern.

PMID: 26625234
DOI: 10.1055/s-0041-107770

Abstract

Monoclonal antibodies against the PD-1 receptor or its ligands result in a recovery of T cell responses against tumor antigens. Nivolumab is the first antibody that has been approved in lung cancer. This mode of action is very intersting, especially because of long term responses and the moderate toxicity.

Publication types

Review

MeSH terms

Antibodies, Monoclonal / adverse effects
Antibodies, Monoclonal / therapeutic use*
Antibodies, Monoclonal, Humanized / adverse effects
Antibodies, Monoclonal, Humanized / therapeutic use
Antigens, Neoplasm / immunology
Drug Approval
Germany
Humans
Immunotherapy / methods*
Lung Neoplasms / drug therapy*
Lung Neoplasms / immunology
Nivolumab
Programmed Cell Death 1 Receptor / antagonists & inhibitors*
Randomized Controlled Trials as Topic
T-Lymphocytes / drug effects
T-Lymphocytes / immunology

Substances

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Antigens, Neoplasm
PDCD1 protein, human
Programmed Cell Death 1 Receptor
Nivolumab
atezolizumab
pembrolizumab